CISION PRNewswire

43401 posts
Agoda and Abu Dhabi's Department of Culture and Tourism Announce Strategic Partnership with Aim to Boost Tourism from Asia

Agoda and Abu Dhabi's Department of Culture and Tourism Announce Strategic Partnership with Aim to Boost Tourism from Asia

SINGAPORE, Dec. 4, 2024 /PRNewswire/ — Digital travel platform Agoda, through its…

Global Times: China-Laos Railway transports 43 million passengers in 3 years, acting as a new engine for regional economic development

BEIJING, Dec. 4, 2024 /PRNewswire/ — As of Monday, the China-Laos Railway…

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved mapping and dual energy ablation catheter

AUSTIN, Texas, Dec. 4, 2024 /PRNewswire/ — Electrophysiologists at the Texas Cardiac…
Top Marketing Campaigns in the Philippines Honored at MMA SMARTIES Philippines 2024

Top Marketing Campaigns in the Philippines Honored at MMA SMARTIES Philippines 2024

MANILA, Philippines, Dec. 4, 2024 /PRNewswire/ —  Bringing together the top innovators…
Singapore's Best Chinese Restaurant, Peach Blossoms, Elevates Chinese Cuisine with Innovative Dishes and Global Collaborations

Singapore's Best Chinese Restaurant, Peach Blossoms, Elevates Chinese Cuisine with Innovative Dishes and Global Collaborations

Nestled within PARKROYAL COLLECTION Marina Bay, Singapore, Peach Blossoms concludes a year marked…
Otis to Equip 68-storey Dawn KLCC with Elevators in Kuala Lumpur, Malaysia

Otis to Equip 68-storey Dawn KLCC with Elevators in Kuala Lumpur, Malaysia

KUALA LUMPUR, Malaysia, Dec. 4, 2024 /PRNewswire/ — Otis (NYSE: OTIS), the world’s leading…
Dahsheng Chemical Launches DURAPONTEX® Grip Insole with Slip-Resistant Technology for Enhanced Athlete Control and Agility

Dahsheng Chemical Launches DURAPONTEX® Grip Insole with Slip-Resistant Technology for Enhanced Athlete Control and Agility

DURAPONTEX Grip® Innovation Offers a High-Performance Solution for Ultimate Movement Control PORTLAND,…

Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy

Patients in the low-dose cohort who have completed 36 weeks of treatment,…